Objective
The use of apixaban in the pediatric cardiac population is expanding. We
describe our apixaban dosing and monitoring strategy in children and
young adults awaiting heart transplantation, along with outcomes related
to bleeding and thrombosis during wait-list and early post-transplant
periods.